Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON COMMERCIAL LAUNCH OF NEFECON® IN MAINLAND CHINA

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that on 14 May 2024, NEFECON® has been commercially launched in Mainland China and successfully fulfilled its first prescription through an internet hospital. This marks the beginning of a new era for immunoglobulin A nephropathy ("**IgAN**") treatment in China and is the first targeted treatment to benefit Chinese IgAN patients.

The Company will employ an innovative commercialization approach of distribution through both traditional and internet hospitals, which can significantly expand patient coverage and enhance their compliance. NEFECON® was approved by the National Medical Products Administration of China for the treatment of primary IgAN in adults at risk of disease progression in November 2023.

China has one of the highest prevalence of primary glomerular diseases in the world with an estimated 5 million IgAN patients, and more than 100,000 newly diagnosed patients annually. There is significant unmet clinical need among IgAN patients. Untreated IgAN patients are at significant risk of kidney failure, which may require dialysis or kidney transplant. At the same time, IgAN has regional and ethnic differences. In particular, the Chinese IgAN population shows more severe pathological changes and faster disease progression. Current non-targeted therapies for IgAN, such as RAS inhibitors, do not fundamentally alter disease progression.

In the Phase 3 NefIgArd study, NEFECON® demonstrated numerically greater magnitude of NEFECON® treatment effect compared with placebo in kidney function, proteinuria and microhematuria. NEFECON® was also safe and well tolerated. Clinical results from Chinese subpopulation analysis showed that NEFECON® reduces kidney function decline by 66% in Chinese subpopulation and expects to delay disease progression to dialysis or kidney transplant by 12.8 years. The launch of NEFECON® fills the gap in the target therapy for IgAN in China, and brings new treatment options to clinicians to benefit disease prognosis and improve disease prognosis.

The Company will broadly and actively commercialize NEFECON® in China and other licensed territories in Asia, and bring this first-in-disease therapy to more patients as soon as possible

INFORMATION ABOUT NEFECON®

NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. In June 2019, the Company entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives the Company exclusive rights to develop and commercialize NEFECON® in Mainland China, Hong Kong, Macau, Taiwan and Singapore. The agreement was extended in March 2022 to include South Korea as part of the Company's territories. NEFECON® was approved by the National Medical Products Administration of China for the treatment of primary IgAN in adults at risk of disease progression in November 2023. NEFECON® has also been approved in various countries in Europe, America and Asia.

Cautionary statement: We cannot guarantee that we will be able to develop, or ultimately market, NEFECON® successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 14 May 2024

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. William Ki Chul Cho and Mr. Honggang Feng as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.